Seebri Neohaler Approval History
FDA Approved: Yes (First approved October 29, 2015)
Brand name: Seebri Neohaler
Generic name: glycopyrrolate
Dosage form: Inhalation Powder
Company: Novartis Pharmaceuticals Corporation
Treatment for: COPD
Seebri Neohaler (glycopyrrolate) is a long-acting muscarinic antagonist (LAMA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Development History and FDA Approval Process for Seebri Neohaler
|Oct 29, 2015||FDA Approves Seebri Neohaler (glycopyrrolate) for COPD|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.